Pfizer Inc. (NYSE:PFE) Shares Acquired by Amica Retiree Medical Trust

Amica Retiree Medical Trust lifted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 53.5% during the 4th quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 17,141 shares of the biopharmaceutical company’s stock after acquiring an additional 5,977 shares during the period. Amica Retiree Medical Trust’s holdings in Pfizer were worth $455,000 at the end of the most recent reporting period.

Several other institutional investors have also recently added to or reduced their stakes in PFE. Delta Asset Management LLC TN lifted its position in shares of Pfizer by 15.8% during the 4th quarter. Delta Asset Management LLC TN now owns 97,994 shares of the biopharmaceutical company’s stock worth $2,600,000 after buying an additional 13,361 shares during the last quarter. AssuredPartners Investment Advisors LLC acquired a new stake in Pfizer during the 4th quarter worth $1,081,000. NEOS Investment Management LLC lifted its position in Pfizer by 31.8% in the fourth quarter. NEOS Investment Management LLC now owns 350,036 shares of the biopharmaceutical company’s stock valued at $9,286,000 after acquiring an additional 84,536 shares during the last quarter. Amica Mutual Insurance Co. boosted its stake in Pfizer by 44.7% in the fourth quarter. Amica Mutual Insurance Co. now owns 157,064 shares of the biopharmaceutical company’s stock valued at $4,167,000 after acquiring an additional 48,541 shares in the last quarter. Finally, UniSuper Management Pty Ltd grew its holdings in shares of Pfizer by 34.8% during the fourth quarter. UniSuper Management Pty Ltd now owns 349,745 shares of the biopharmaceutical company’s stock worth $9,279,000 after purchasing an additional 90,289 shares during the last quarter. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of NYSE PFE opened at $25.19 on Thursday. The company’s fifty day moving average is $26.12 and its two-hundred day moving average is $26.98. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The firm has a market capitalization of $142.88 billion, a P/E ratio of 17.87, a PEG ratio of 0.64 and a beta of 0.61. Pfizer Inc. has a one year low of $24.48 and a one year high of $31.54.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s quarterly revenue was up 24.7% compared to the same quarter last year. During the same period last year, the company posted $0.10 earnings per share. Analysts forecast that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Insider Buying and Selling

In other news, Director Ronald E. Blaylock purchased 19,457 shares of the business’s stock in a transaction dated Thursday, February 13th. The stock was acquired at an average price of $25.65 per share, with a total value of $499,072.05. Following the purchase, the director now directly owns 27,707 shares of the company’s stock, valued at $710,684.55. This represents a 235.84 % increase in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by insiders.

Analysts Set New Price Targets

A number of brokerages recently issued reports on PFE. Citigroup decreased their target price on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Bank of America restated a “neutral” rating and set a $29.00 target price on shares of Pfizer in a research report on Tuesday, December 10th. Hsbc Global Res upgraded shares of Pfizer to a “strong-buy” rating in a research report on Monday, March 10th. Truist Financial lowered their price objective on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating on the stock in a research report on Wednesday, December 18th. Finally, Guggenheim reiterated a “buy” rating on shares of Pfizer in a research note on Tuesday, March 18th. One research analyst has rated the stock with a sell rating, seven have issued a hold rating, six have given a buy rating and three have assigned a strong buy rating to the company’s stock. According to MarketBeat, Pfizer presently has a consensus rating of “Moderate Buy” and a consensus price target of $31.92.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.